Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 11/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21465642 | 0.86 | PPARG (0.56) | MAPK8MAPK9PPARG | |
| SCHEMBL21465564 | 0.85 | MAPK8 (0.47) | MAPK8MAPK9PPARGHPGDMAPT | |
| SCHEMBL9538268 | 0.81 | MAPK8 (0.52) | MAPK8MAPK9HPGDMAPTPKM | |
| SCHEMBL23759961 | 0.80 | ABCB11 (0.55) | MAPK8PPARGMAPTPKMALOX15 | |
| SCHEMBL27291037 | 0.79 | MAPK8 (0.55) | MAPK8MAPK9 | |
| SCHEMBL8117298 | 0.79 | MAPK8 (0.49) | MAPK8MAPK9PPARGMAPTMAPK1 | |
| SCHEMBL10461275 | 0.78 | KDM4E (0.52) | MAPK8MAPK9HPGDMAPTPKM | |
| SCHEMBL9537544 | 0.78 | MAPK8 (0.56) | MAPK8MAPK9HPGDMAPTPKM | |
| SCHEMBL10758715 | 0.78 | KDM4E (0.58) | MAPK8PPARGHPGDMAPTPKM | |
| SCHEMBL10462673 | 0.77 | KDM4E (0.48) | MAPK8MAPK9HPGDMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690824-B2 | Antibacterial compounds | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690824-B2 | Antibacterial compounds | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690824-B2 | Antibacterial compounds | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210251958-A1 | Antibacterial Compounds | RHODE ISLAND HOSPITAL, A LIFESPAN-PARTNER | 2021-08-19 | — | — | US | disclosed |
| US-20210251958-A1 | Antibacterial Compounds | RHODE ISLAND HOSPITAL, A LIFESPAN-PARTNER | 2021-08-19 | — | — | US | disclosed |
| WO-2019199979-A1 | ANTIBACTERIAL COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019199979-A1 | ANTIBACTERIAL COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690824-B2 | Antibacterial compounds | MRPL21, SPOUT1, BAX | MAPK8 2205/4885MAPK9 2175/4885PPARG 2093/4885 |
| US-20210251958-A1 | Antibacterial Compounds | MRPL21, SPOUT1, BAX | MAPK8 2205/4885MAPK9 2175/4885PPARG 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.